Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5.

Nattermann J, Nischalke HD, Feldmann G, Ahlenstiel G, Sauerbruch T, Spengler U.

J Viral Hepat. 2004 Nov;11(6):519-26.

PMID:
15500552
2.

Regulation of CC chemokine receptor 5 in hepatitis G virus infection.

Nattermann J, Nischalke HD, Kupfer B, Rockstroh J, Hess L, Sauerbruch T, Spengler U.

AIDS. 2003 Jul 4;17(10):1457-62.

PMID:
12824783
3.

Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C.

Nattermann J, Zimmermann H, Iwan A, von Lilienfeld-Toal M, Leifeld L, Nischalke HD, Langhans B, Sauerbruch T, Spengler U.

Hepatology. 2006 Oct;44(4):945-54.

PMID:
17006905
4.

Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection.

Lichterfeld M, Leifeld L, Nischalke HD, Rockstroh JK, Hess L, Sauerbruch T, Spengler U.

J Infect Dis. 2002 Jun 15;185(12):1803-7. Epub 2002 May 20.

PMID:
12085329
5.

IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes.

Losana G, Bovolenta C, Rigamonti L, Borghi I, Altare F, Jouanguy E, Forni G, Casanova JL, Sherry B, Mengozzi M, Trinchieri G, Poli G, Gerosa F, Novelli F.

J Leukoc Biol. 2002 Oct;72(4):735-42.

PMID:
12377943
6.

Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets.

Yamada E, Montoya M, Schuettler CG, Hickling TP, Tarr AW, Vitelli A, Dubuisson J, Patel AH, Ball JK, Borrow P.

J Gen Virol. 2005 Sep;86(Pt 9):2507-12.

PMID:
16099909
7.

Lower expression of CD81 B-cell receptor in lymphoproliferative diseases associated with hepatitis C virus infection.

Cacoub P, Bourlière M, Hausfater P, Charlotte F, Khiri H, Toci S, Piette JC, Poynard T, Halfon P.

J Viral Hepat. 2003 Jan;10(1):10-5.

PMID:
12558906
8.
9.

Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression.

Kronenberger B, Sarrazin C, Hofmann WP, von Wagner M, Herrmann E, Welsch C, Elez R, Rüster B, Piiper A, Zeuzem S.

J Viral Hepat. 2004 Jul;11(4):310-8.

PMID:
15230853
10.

Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells.

Mazzocca A, Sciammetta SC, Carloni V, Cosmi L, Annunziato F, Harada T, Abrignani S, Pinzani M.

J Biol Chem. 2005 Mar 25;280(12):11329-39. Epub 2004 Dec 16.

11.

CD81 expression on CD19+ peripheral blood lymphocytes is associated with chronic HCV disease and increased risk for HCV infection: a putative role for inflammatory cytokines.

D'Agosto G, Trento E, Nosotti L, Bordignon V, Battista M, Prignano G, Pimpinelli F, Biolcati G, Macrì A, Palamara G, Miglioresi L, Morrone A, Di Carlo A, Cordiali-Fei P, Ensoli F.

J Biol Regul Homeost Agents. 2009 Jul-Sep;23(3):155-64.

PMID:
19828092
12.

Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity.

Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham PR, Signoret N, Marsh M, Stangassinger M, Borlat F, Wells TN, Schlöndorff D, Proudfoot AE.

J Exp Med. 1998 Apr 20;187(8):1215-24.

13.

Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia.

Ahlenstiel G, Woitas RP, Iwan A, Nattermann J, Feldmann G, Rockstroh JK, Oldenburg J, Kupfer B, Sauerbruch T, Spengler U.

Immunol Invest. 2009;38(1):1-13. doi: 10.1080/08820130802307294.

PMID:
19172482
14.

I-TAC/CXCL11 is a natural antagonist for CCR5.

Petkovic V, Moghini C, Paoletti S, Uguccioni M, Gerber B.

J Leukoc Biol. 2004 Sep;76(3):701-8. Epub 2004 Jun 3.

PMID:
15178708
15.

Increased CCR5 expression with decreased beta chemokine secretion in Ethiopians: relevance to AIDS in Africa.

Kalinkovich A, Weisman Z, Leng Q, Borkow G, Stein M, Greenberg Z, Zlotnikov S, Eitan S, Bentwich Z.

J Hum Virol. 1999 Sep-Oct;2(5):283-9.

PMID:
10551734
16.

Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C.

Kronenberger B, Herrmann E, Hofmann WP, Wedemeyer H, Sester M, Mihm U, Ghaliai T, Zeuzem S, Sarrazin C.

J Leukoc Biol. 2006 Aug;80(2):298-308. Epub 2006 May 30.

PMID:
16735696
17.

The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection.

Larrubia JR, Calvino M, Benito S, Sanz-de-Villalobos E, Perna C, Pérez-Hornedo J, González-Mateos F, García-Garzón S, Bienvenido A, Parra T.

J Hepatol. 2007 Nov;47(5):632-41. Epub 2007 May 24.

PMID:
17560677
18.

Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders.

Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D'Oro U, Nuti S, Houghton M, Barnaba V, Pozzato G, Abrignani S.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18544-9. Epub 2005 Dec 9.

19.

The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density.

Desmetz C, Lin YL, Mettling C, Portalès P, Rabesandratana H, Clot J, Corbeau P.

Immunology. 2006 Dec;119(4):551-61.

20.

Aberrant responsiveness to RANTES in synovial fluid T cells from patients with rheumatoid arthritis.

Hisakawa N, Tanaka H, Hosono O, Nishijima R, Ohashi Y, Saito S, Nishiya K, Hashimoto K, Morimoto C.

J Rheumatol. 2002 Jun;29(6):1124-34.

PMID:
12064824

Supplemental Content

Support Center